Allogene Advances Off-The-Shelf Mission With Pivotal Trial Progress, Solid Tumor Data

Allogene Therapeutics Inc. achieved a big first for allogeneic chimeric antigen receptor T-cell (CAR-T) therapies last year when it initiated the Phase II ALPHA2 clinical trial of its CD19-targeting ALLO-501A in third-line or later treatment of diffuse large B-cell lymphoma (DLBCL). This year, the company achieved another big milestone when it reported initial results from the ongoing Phase I TRAVERSE trial of ALLO-316, a CD70-targeting candidate, in advanced or metastatic renal cell carcinoma (RCC), providing proof-of-concept data for its allogeneic CAR-T approach in solid tumors.

Executive vice president of research and development, and chief medical officer, Zachary Roberts described in an interview with Scrip how...